Asundexian (Sunharbo)
To reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack
In 14,810 high-risk patients with atrial fibrillation, asundexian 50 mg daily gave more stroke or systemic embolism than apixaban (1.3% vs 0.4%; HR 3.79) in a trial stopped early, though major bleeding was lower (0.2% vs 0.7%; HR 0.32). Clinical trial · phase 3 · n = 14,810 · N Engl J Med · 2024
In 12,327 patients with noncardioembolic ischaemic stroke or high-risk TIA on antiplatelet therapy, asundexian 50 mg daily cut ischaemic stroke vs placebo (6.2% vs 8.4%; HR 0.74) without more major bleeding (1.9% vs 1.7%). RCT · phase 3 · n = 12,327 · N Engl J Med · 2026